Publications for Anna deFazio 2016

Publications for Anna deFazio

2016

Harrington, B., he, Y., Davies, C., Wallace, S.,

Adams, M., Beaven, E., Roche, D., Kennedy, C.,

Chetty, N., Crandon, A., deFazio, A., et al

(2016). Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. British Journal of Clinical Pharmacology , 114(4), 417-426. <a href="http://dx.doi.org/10.1038/bjc.2015.471">[

More Information]</a>

Price, M., Butow, P., Bell, M., deFazio, A.,

Friedlander, M., Fardell, J., Protani, M., Webb,

P. (2016). Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making. Supportive Care in Cancer . <a href="http://dx.doi.org/10.1007/s00520-015-307

0-5">[More Information]</a>

Winham, S., Pirie, A., Chen, Y., Larson, M.,

Fogarty, Z., Earp, M., Anton-Culver, H.,

Bandera, E., Cramer, D., deFazio, A.,

Chenevix-Trench, G., et al (2016). Investigation of exomic variants associated with overall survival in ovarian cancer. Cancer

Epidemiology, Biomarkers and Prevention ,

25(3), 446-454. <a href="http://dx.doi.org/10.1158/1055-9965.EPI-1


Hollestelle, A., van der Baan, F., Berchuck, A.,

Johnatty, S., Aben, K., Agnarsson, B., Aittomaki,

K., Alducci, E., Andrulis, I., Balleine, R., Carter,

J., deFazio, A., et al (2016). No clinical utility of

KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology , 141(2), 386-401.

<a href="http://dx.doi.org/10.1016/j.ygyno.2015.04.

034">[More Information]</a>

2015

Nagle, C., Ibiebele, T., deFazio, A., Protani, M.,

Webb, P. (2015). Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival.

Cancer Epidemiology , 39(2), 196-199. <a href="http://dx.doi.org/10.1016/j.canep.2014.12.


Webb, P., deFazio, A., Protani, M., Ibiebele, T.,

Nagle, C., Brand, A., Blomfield, P., Grant, P.,

Perrin, L., Neale, R. (2015). Circulating

25-hydroxyvitamin D and survival in women with ovarian cancer. The American Journal of

Clinical Nutrition , 102(1), 109-114. <a href="http://dx.doi.org/10.3945/ajcn.114.102681

">[More Information]</a>

Lawrenson, K., Li, Q., Kar, S., Seo, J., Tyrer, J.,

Publications for Anna deFazio

Spindler, T., Lee, J., Chen, Y., Karst, A.,

Drapkin, R., et al (2015). Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer.

Nature Communications , 6, 1-14. <a href="http://dx.doi.org/10.1038/ncomms9234">[


Johnatty, S., Tyrer, J., Kar, S., Beesley, J., Lu,

Y., Gao, B., Fasching, P., Hein, A., Ekici, A.,

Beckmann, M., Kennedy, C., Chiew, Y., deFazio, A., et al (2015). Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian

Cancer Association Consortium. Clinical Cancer

Research , 21(23), 5264-5276. <a href="http://dx.doi.org/10.1158/1078-0432.CCR-


Candido-dos-Reis, F., Song, H., Goode, E.,

Cunningham, J., Fridley, B., Larson, M., Alsop,

K., Dicks, E., Harrington, P., Ramus, S., deFazio, A., et al (2015). Germline Mutation in

BRCA1 or BRCA2 and Ten-Year Survival for

Women Diagnosed with Epithelial Ovarian

Cancer. Clinical Cancer Research , 21(3),

652-657. <a href="http://dx.doi.org/10.1158/1078-0432.CCR-


French, J., Johnatty, S., Lu, Y., Beesley, J., Gao,

B., Kalimutho, M., Henderson, M., Russell, A.,

Kar, S., Chen, X., Harnett, P., deFazio, A., et al

(2015). Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget ,

7(6), 6353-6368. <a href="http://dx.doi.org/10.18632/oncotarget.704


Lei, Y., Henderson, B., Emmanuel, C., Harnett,

P., deFazio, A. (2015). Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis.

Oncogene , 34(4), 485-495. <a href="http://dx.doi.org/10.1038/onc.2013.566">[


Hunter, S., Anglesio, M., Ryland, G., Sharma,

R., Chiew, Y., Rowley, S., Doyle, M., Li, J.,

Gilks, B., Moss, P., deFazio, A., et al (2015).

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.

Oncotarget , 6(35), 37663-37677. <a href="http://dx.doi.org/10.18632/oncotarget.543


Nagle, C., Dixon, S., Jensen, A., Kjaer, S.,

Modugno, F., deFazio, A., Feredaye, S., Hung,

J., Johnatty, S., Fasching, P., et al (2015).

Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer

Association Consortium. British Journal of

Cancer , 113(5), 817-826. <a

Publications for Anna deFazio href="http://dx.doi.org/10.1038/bjc.2015.245">[


Tembe, V., Martino-Echarri, E., Marzec, K.,

Mok, M., Brodie, K., Mills, K., Lei, Y., deFazio,

A., Rizos, H., Kettle, E., Henderson, B., et al

(2015). The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function. Cellular

Signalling , 27(9), 1763-1771. <a href="http://dx.doi.org/10.1016/j.cellsig.2015.05.


Patch, A., Christie, E., Etemadmoghadam, D.,

Garsed, D., George, J., Fereday, S., Nones, K.,

Cowin, P., Alsop, K., Bailey, P., Kennedy, C.,

Hung, J., Chiew, Y., Harnett, P., McNally, O., deFazio, A., et al (2015). Whole-genome characterization of chemoresistant ovarian cancer. Nature , 521(7553), 489-494. <a href="http://dx.doi.org/10.1038/nature14410">[


2014

Hedditch, E., Gao, B., Russell, A., Li, Y.,

Emmanuel, C., Beesley, J., Johnatty, S., Chen,

X., Harnett, P., George, J., deFazio, A., et al

(2014). ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.

Journal of the National Cancer Institute , 106(7),

1-11. <a href="http://dx.doi.org/10.1093/jnci/dju149">[M ore Information]</a>

Butow, P., Price, M., Bell, M., Webb, P., deFazio, A., Friedlander, M. (2014). Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs. Gynecologic

Oncology , 132(3), 690-697. <a href="http://dx.doi.org/10.1016/j.ygyno.2014.01.


Dixon, S., Ibiebele, T., Protani, M., Beesley, J., deFazio, A., Crandon, A., Gard, G., Rome, R.,

Webb, P., Nagle, C. (2014). Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival. Gynecologic

Oncology , 132(3), 566-572. <a href="http://dx.doi.org/10.1016/j.ygyno.2013.12.


Kobel, M., Madore, J., Ramus, S., Clarke, B.,

Pharoah, P., Deen, S., Bowtell, D., Odunsi, K.,

Menon, U., Morrison, C., deFazio, A., et al

(2014). Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue

Analysis consortium study. British Journal of

Cancer , 111(12), 2297-2307. <a href="http://dx.doi.org/10.1038/bjc.2014.567">[


Ghoussaini, M., Edwards, S., Michailidou, K.,

Nord, S., Cowper-Sal-lari, R., Desai, K., Kar, S.,

Hillman, K., Kaufmann, S., Glubb, D., deFazio,

A., et al (2014). Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications , 4, 1-12. <a href="http://dx.doi.org/10.1038/ncomms5999">[


Emmanuel, C., Chiew, Y., George, J.,

Etemadmoghadam, D., Anglesio, M., Sharma,

R., Russell, P., Kennedy, C., Fereday, S., Hung,

J., Hogg, R., Wain, G., Brand, A., Balleine, R.,

Clarke, C., Harnett, P., deFazio, A., et al (2014).

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies

NRAS as an oncogenic driver. Clinical Cancer



Au-Yeung, G., Webb, P., deFazio, A., Feredaye,

S., Bressel, M., Mileshkin, L. (2014). Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the

Australian Ovarian Cancer Study (AOCS).

Gynecologic Oncology , 133(1).

Charbonneau, B., Moysich, K., Kalli, K., Oberg,

A., Vierkant, R., Fogarty, Z., Block, M., Maurer,

M., Goergen, K., Fridley, B., deFazio, A., et al

(2014). Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunology

Research , 2(4), 332-340. <a href="http://dx.doi.org/10.1158/2326-6066.CIR-


Gao, B., Russell, A., Beesley, J., Chen, X.,

Healey, S., Henderson, M., Wong, K.,

Emmanuel, C., Galletta, L., Johnatty, S., Harnett,

P., Balleine, R., deFazio, A., et al (2014).

Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Scientific

Reports , 4, 1-9. <a href="http://dx.doi.org/10.1038/srep04669">[Mo re Information]</a>

Beesley, V., Green, A., Wyld, D., O'Rourke, P.,

Wockner, L., deFazio, A., Butow, P., Price, M.,

Horwood, K., Clavarino, A., et al (2014). Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: A prospective analysis. Gynecologic Oncology ,

132(1), 130-136. <a href="http://dx.doi.org/10.1016/j.ygyno.2013.10.


Block, M., Charbonneau, B., Vierkant, R.,

Fogarty, Z., Bamlet, W., Pharoah, P.,

Chenevix-Trench, G., Rossing, M., Cramer, D.,


Pearce, C., deFazio, A., et al (2014). Variation in

NF-κB signaling pathways and survival in invasive epithelial ovarian cancer. Cancer

Epidemiology, Biomarkers and Prevention ,

23(7), 1421-1427. <a href="http://dx.doi.org/10.1158/1055-9965.EPI-1


2013

Johnatty, S., Beesley, J., Gao, B., Chen, X., Lu,

Y., Law, M., Henderson, M., Russell, A.,

Hedditch, E., Emmanuel, C., deFazio, A., et al

(2013). ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer

Association Consortium and The Cancer

Genome Atlas. Gynecologic Oncology , 131(1),

8-14. <a href="http://dx.doi.org/10.1016/j.ygyno.2013.07.


White, K., Vierkant, R., Fogarty, Z.,

Charbonneau, B., Block, M., Pharoah, P.,

Chenevix-Trench, G., Rossing, M., Cramer, D.,

Pearce, C., deFazio, A., et al (2013). Analysis of

Over 10,000 Cases Finds No Association between Previously Reported Candidate

Polymorphisms and Ovarian Cancer Outcome.

Cancer Epidemiology, Biomarkers and

Prevention , 22(5), 987-992. <a href="http://dx.doi.org/10.1158/1055-9965.EPI-1


Baumbusch, L., Helland, A., Wang, Y., Liestöl,

K., Schaner, M., Holm, R., Etemadmoghadam,

D., Alsop, K., Brown, P., Mitchell, G., deFazio,

A., et al (2013). High Levels of Genomic

Aberrations in Serous Ovarian Cancers Are

Associated with Better Survival. PloS One , 8(1),

1-8. <a href="http://dx.doi.org/10.1371/journal.pone.005


Sieh, W., Kobel, M., Longacre, T., Bowtell, D., deFazio, A., Goodman, M., Hogdall, E., Deen,

S., Wentzensen, N., Moysich, K., et al (2013).

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. The Lancet Oncology , 14(9),

853-862. <a href="http://dx.doi.org/10.1016/S1470-2045(13)


George, J., Alsop, K., Etemadmoghadam, D.,

Hondow, H., Mikeska, T., Dobrovic, A., deFazio, A., Smyth, G., Levine, D., Mitchell, G., et al (2013). Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clinical Cancer Research , 19(13),



Jordan, S., Steer, C., deFazio, A., Quinn, M.,

Obermair, A., Friedlander, M., Francis, J.,

O'Brien, S., Goss, G., Wyld, D., et al (2013).

Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - a population-based study. Gynecologic Oncology ,

129(2), 310-317. <a href="http://dx.doi.org/10.1016/j.ygyno.2013.02.


Price, M., Bell, M., Sommeijer, D., Friedlander,

M., Stockler, M., deFazio, A., Webb, P., Butow,

P. (2013). Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life. Gynecologic Oncology , 130(1),

162-168. <a href="http://dx.doi.org/10.1016/j.ygyno.2013.03.


Verhaak, R., Tamayo, P., Yang, J., Hubbard, D.,

Zhang, H., Creighton, C., Fereday, S., Lawrence,

M., Carter, S., Mermel, C., deFazio, A., et al

(2013). Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. Journal of Clinical Investigation , 123(1), 517-525. <a href="http://dx.doi.org/10.1172/JCI65833">[Mor e Information]</a>

2012

Alsop, K., Fereday, S., Meldrum, C., deFazio,

A., Emmanuel, C., George, J., Dobrovic, A.,

Birrer, M., Webb, P., Stewart, C., et al (2012).

BRCA Mutation Frequency and Patterns of

Treatment Response in BRCA Mutation-Positive

Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group.

Journal of Clinical Oncology , 30(21),

2654-2663. <a href="http://dx.doi.org/10.1200/JCO.2011.39.85


Lu, Y., Chen, X., Beesley, J., Johnatty, S., deFazio, A., Lambrechts, S., Lambrechts, D.,

Despierre, E., Vergotes, I., Chang-Claude, J., et al (2012). Genome-Wide Association Study for

Ovarian Cancer Susceptibility Using Pooled

DNA. Twin Research and Human Genetics ,

15(5), 615-623. <a href="http://dx.doi.org/10.1017/thg.2012.38">[


Cowin, P., George, J., Fereday, S., Loehrer, E.,

Van Loo, P., Cullinane, C., Etemadmoghadam,

D., Ftouni, S., Galletta, L., Anglesio, M.,

Harnett, P., deFazio, A., et al (2012). LRP1B

Deletion in High-Grade Serous Ovarian Cancers

Is Associated with Acquired Chemotherapy

Resistance to Liposomal Doxorubicin. Cancer

Research , 72(16), 4060-4073. <a href="http://dx.doi.org/10.1158/0008-5472.CAN

-12-0203">[More Information]</a>

Wang, Z., Birkbak, N., Culhane, A., Drapkin, R.,

Fatima, A., Tian, R., Schwede, M., Alsop, K.,

Daniels, K., Piao, H., deFazio, A., et al (2012).

Profiles of Genomic Instability in High-Grade

Serous Ovarian Cancer Predict Treatment

Outcome. Clinical Cancer Research , 18(20),



2011

Emmanuel, C., Gava, N., Kennedy, C., Balleine,

R., Sharma, R., Wain, G., Brand, A., Hogg, R.,

Etemadmoghadam, D., George, J., Clarke, C.,

Harnett, P., deFazio, A., et al (2011).

Comparison of Expression Profiles in Ovarian

Epithelium In Vivo and Ovarian Cancer

Identifies Novel Candidate Genes Involved in

Disease Pathogenesis. PloS One , 6(3), e17617-1-e17617-18. <a href="http://dx.doi.org/10.1371/journal.pone.001


Hunter, S., Anglesio, M., Sharma, R., Gilks, B.,

Melnyk, N., Chiew, Y., deFazio, A., Longacre,

T., Huntsman, D., Gorringe, K., et al (2011).

Copy Number Aberrations in Benign Serous

Ovarian Tumors: A Case for Reclassification?

Clinical Cancer Research , 17(23), 7273-7282.

<a href="http://dx.doi.org/10.1158/1078-0432.CCR-


Helland, A., Anglesio, M., George, J., Cowin, P.,

Johnstone, C., House, C., Sheppard, K.,

Etemadmoghadam, D., Melnyk, N., Rustgi, A., deFazio, A., et al (2011). Deregulation of

MYCN, LIN28B and LET7 in a Molecular

Subtype of Aggressive High-Grade Serous

Ovarian Cancers. PloS One , 6(4), 1-9. <a href="http://dx.doi.org/10.1371/journal.pone.001


Anglesio, M., George, J., Kulbe, H., Friedlander,

M., Rischin, D., Lemech, C., Power, J., Coward,

J., Cowin, P., House, C., deFazio, A., et al

(2011). IL6-STAT3-HIF Signaling and

Therapeutic Response to the Angiogenesis

Inhibitor Sunitinib in Ovarian Clear Cell Cancer.

Clinical Cancer Research , 17(8), 2538-2548. <a href="http://dx.doi.org/10.1158/1078-0432.CCR-


Huang, S., Johnatty, S., Gamazon, E., Kyung Im,

H., Ziliak, D., Duan, S., Zhang, W., O' Kistner,

E., Chen, P., Beesley, J., deFazio, A., et al

(2011). Platinum Sensitivity-Related Germline

Polymorphism Discovered via a Cell-Based

Approach and Analysis of Its Association with

Outcome in Ovarian Cancer Patients. Clinical

Cancer Research , 17(16), 5490-5500. <a href="http://dx.doi.org/10.1158/1078-0432.CCR-


Nagle, C., Francis, J., Nelson, A., Zorbas, H.,


Luxford, K., deFazio, A., Fereday, S., Bowtell,

D., Green, A., Webb, P. (2011). Reducing Time to Diagnosis Does Not Improve Outcomes for

Women With Symptomatic Ovarian Cancer: A

Report From the Australian Ovarian Cancer

Study Group. Journal of Clinical Oncology ,

29(16), 2253-2258. <a href="http://dx.doi.org/10.1200/JCO.2010.32.21


McConechy, M., Anglesio, M., Kalloger, S.,

Yang, W., Senz, J., Chow, C., Heravi-Moussavi,

A., Morin, G., deFazio, A., Mes-Masson, A., et al (2011). Subtype-specific mutation of

PPP2R1A in endometrial and ovarian carcinomas. Journal of Pathology , 223(5),

567-573. <a href="http://dx.doi.org/10.1002/path.2848">[Mo re Information]</a>

Pharoah, P., Palmieri, R., Ramus, S., Gayther, S.,

Andrulis, I., Anton-Culver, H., Antonenkova, N.,

Antoniou, A., Goldgar, D., deFazio, A., Gao, B.,

Harnett, P., et al (2011). The Role of KRAS rs61764370 in Invasive Epithelial Ovarian

Cancer: Implications for Clinical Testing.




2010

Johal, H., Faedo, M., Faltas, J., Lau, A.,

Mousina, R., Cozzi, P., deFazio, A., Rawlinson,

W. (2010). DNA of mouse mammary tumor virus-like virus is present in human tumors influenced by hormones. Journal of Medical

Virology , 82(6), 1044-1050. <a href="http://dx.doi.org/10.1002/jmv.21754">[M ore Information]</a>

Ahmed Ashoure, A., Etemadmoghadam, D.,

Temple, J., Lynch, A., Riad, M., Sharma, R.,

Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al (2010). Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. Journal of Pathology , 221(1), 49-56. <a href="http://dx.doi.org/10.1002/path.2696">[Mo re Information]</a>

Johnatty, S., Beesley, J., Chen, X., MacGregor,

S., Duffy, D., Spurdle, A., deFazio, A., Gava, N.,

Webb, P., Rossing, M., et al (2010). Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility

"hot-spot". PLoS Genetics , 6(7), e1001016 -

1-e1001016 - 10. <a href="http://dx.doi.org/10.1371/journal.pgen.100


Hudson, T., Anderson, W., Aretz, A., Barker, A.,

Bell, C., Bernabe, R., Bhan, M., Calvo, F.,

Eerola, I., Gerhard, D., deFazio, A., Kench, J., et

Publications for Anna deFazio al (2010). International network of cancer genome projects. Nature , 464, 993-998. <a href="http://dx.doi.org/10.1038/nature08987">[


Byrne, J., Maleki, S., Hardy, J., Gloss, B.,

Murali, R., Scurry, J., Fanayan, S., Emmanuel,

C., Hacker, N., Sutherland, R., deFazio, A., et al

(2010). MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC

Cancer , 10(497), 1-11. <a href="http://dx.doi.org/10.1186/1471-2407-10-4


Gordon, L., Scuffham, P., Beesley, V., Green,

A., deFazio, A., Wyld, D., Clavarino, A.,

Australian Ovarian Cancer Study Group, (.,

Webb, P. (2010). Medical costs and outcomes for

Australian women with ovarian cancer: a patient-level analysis over 2.5 years.

International Journal of Gynecological Cancer ,

20(5), 757-765. <a href="http://dx.doi.org/10.1111/IGC.0b013e3181

dbd13f">[More Information]</a>

Price, M., Butow, P., Costa, D., King, M.,

Aldridge, L., Fardell, J., deFazio, A., Webb, P.

(2010). Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers. Medical Journal of

Australia , 193(5), S52-S57. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.

fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract

&list_uids=20819029">[More Information]</a>

2009

Etemadmoghadam, D., deFazio, A., Beroukhim,

R., Mermel, C., George, J., Getz, G., Tothill, R.,

Okamoto, A., Raeder, M., Harnett, P., Chiew, Y., et al (2009). Integrated genome-wide DMA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clinical Cancer



Shah, S., Kobel, M., Senz, J., Morin, R., Clarke,

B., Wiegand, K., Leung, G., Zayed, A., deFazio,

A., Bowtell, D. (2009). Mutation of FOXL2 in granulosa-cell tumors of the ovary. New England

Journal of Medicine , 360(26), 2719-2729. <a href="http://dx.doi.org/10.1056/NEJMoa090254


Johnatty, S., Beesley, J., Chen, X., Spurdle, A., deFazio, A., Webb, P., Goode, E., Rider, D.,

Vierkant, R., Anderson, S. (2009).

Polymorphisms in the FGF2 Gene and Risk of

Serous Ovarian Cancer: Results From the

Ovarian Cancer Association Consortium. Twin

Research and Human Genetics , 12(3), 269-275.

<a href="http://dx.doi.org/10.1375/twin.12.3.269">[


Price, M., Zachariae, R., Butow, P., deFazio, A.,

Patel (nee Chauhan), D., Espie, C., Friedlander,

M., Webb, P. (2009). Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor. European

Journal of Cancer , 45(18), 3262-3270. <a href="http://dx.doi.org/10.1016/j.ejca.2009.05.03


2008

Johnatty, S., Beesley, J., Paul, J., Fereday, S.,

Spurdle, A., Webb, P., Byth, K., Marsh, S.,

McLeod, H., AOCS, S., Harnett, P., deFazio, A., et al (2008). ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clinical

Cancer Research , 14(17), 5594-5601. <a href="http://dx.doi.org/10.1158/1078-0432.CCR-


Scurr, L., Guminski, A., Chiew, Y., Balleine, R.,

Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand,

A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1,

ANKRD1, a Novel Determinant of Cisplatin

Sensitivity Expressed in Ovarian Cancer.




Gava, N., Clarke, C., Bye, C., Byth Wilson, K., deFazio, A. (2008). Global gene expression profiles of ovarian surface epithelial cells in vivo. Journal of Molecular Endocrinology , 40,

281-296. <a href="http://dx.doi.org/10.1677/JME-07-0149">[


Anglesio, M., Arnold, J., George, J., Tinker, A.,

Tothill, R., Waddell, N., Simms, L., Locandro,

B., Fereday, S., Traficante, N., Russell, P., deFazio, A., et al (2008). Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

Molecular Cancer Research , 6(11), 1678-1690.

<a href="http://dx.doi.org/10.1158/1541-7786.MCR

-08-0193">[More Information]</a>

Tothill, R., Tinker, A., George, J., Brown, R.,

Fox, S., Lade, S., Johnson,, D., Trivett, M.,

Etemadmoghadam, D., Locandro, B., deFazio,

A., et al (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical Cancer Research ,

14(16), 5198-5208. <a href="http://dx.doi.org/10.1158/1078-0432.CCR-



O'Brien, P., Davies, M., Scurry, J., Smith, A.,

Barton, C., Henderson, M., Saunders, D., Gloss,

B., Patterson, K., et, A., Murali, R., Scolyer, R.,

Scurr, L., deFazio, A. (2008). The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. British Journal of

Cancer , 98(6), 1085-1093. <a href="http://dx.doi.org/10.1038/sj.bjc.6604281">

[More Information]</a>

2007

Krypuy, M., Ahmed Ashoure, A.,

Etemadmoghadam, D., Hyland, S., deFazio, A.,

Fox, S., Brenton, J., Bowtell, D., Dobrovic, A.

(2007). High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer ,

7(open access), 1-13. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.



Greenman, C., Vastrik, I., Cahill, D., Goldstraw,

P., Brasseur, F., Looijenga, L., Weber, B.,

Chiew, Y., deFazio, A., Greaves, M., et al

(2007). Patterns of somatic mutation in human cancer genomes. Nature , 446(7132), 153-158. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.



Catchpoole, D., deFazio, A., Devereaux, L., Hof,

M., Schmidt, C., Thorne, H., Zeps, N., Fleming,

M. (2007). The importance of biorepository networks: The Australasian Biospecimen

Network-Oncology. Australian Journal of

Medical Science , 28(1), 16-20.

2006

Arnett-Mansfield, R., Graham, J., Hanson, A.,

Mote, P., Gompel, A., Scurr, L., Gava, N., deFazio, A., Clarke, C. (2006). Focal subnuclear distribution of progesterone receptor is ligand-dependent and associated with transcriptional activity. Molecular

Endocrinology , 21(1), 14-29. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.



Guminski, A., Balleine, R., Chiew, Y., Webster,

L., Tapner, M., Farrell, G., Harnett, P., deFazio,

A. (2006). MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology , 100(2),

239-246. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.



Mote, P., Arnett-Mansfield, R., Gava, N., deFazio, A., Mulac-Jericevic, B., Conneely, O.,

Clarke, C. (2006). Overlapping and distinct expression of progesterone receptors A and B in mouse uterus and mammary gland during the estrous cycle. Endocrinology , 147(12),

5503-5512. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.



2005 deFazio, A., Harnett, P., Guminski, A. (2005).

Patent Families: Determinants of sensitivity to chemotherapeutic agents. Patent No.

2005316200 .

Aghmesheh, M., Edwards, L., Clarke, C., Byth

Wilson, K., Katzenellenbogen, B., Russell, P.,

Friedlander, M., Tucker, K., deFazio, A. (2005).

Expression of steroid hormone receptors in

BRCA1-associated ovarian carcinomas.

Gynecologic Oncology , 97(1), 16-25. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.



Byrne, J., Balleine, R., Fejzo, M., Mercieca, J.,

Chiew, Y., Livnat, Y., St.Heaps, L., Peters, G.,

Byth Wilson, K., Karlan, B., Harnett, P., deFazio, A., et al (2005). Tumor protein D52

(TPD52) is overexpressed and a gene amplification target in ovarian cancer.

International Journal of Cancer , 117(6),

1049-54. <a href="http://dx.doi.org/10.1002/ijc.21250">[Mor e Information]</a>

2004

Balleine, R., Earls, P., Webster, L., Mote, P., deFazio, A., Harnett, P., Clarke, C. (2004).

Expression Of Progesterone Receptor A And B

Isoforms In Low-Grade Endometrial Stromal

Sarcoma. International Journal of Gynecological

Pathology , 23(2), 138-144.

Gava, N., Clarke, C., Byth Wilson, K.,

Arnett-Mansfield, R., deFazio, A. (2004).

Expression Of Progesterone Receptors A And B

In The Mouse Ovary During The Estrous Cycle.

Endocrinology , 145(7), 3487-3494.

Arnett-Mansfield, R., deFazio, A., Mote, P.,

Clarke, C. (2004). Subnuclear Distribution Of

Progesterone Receptors A And B In Normal And

Malignant Endometrium. Journal of Clinical

Endocrinology and Metabolism , 89(3),

1429-1442.

2002

Kennedy, C., Byth, K., Clarke, C., deFazio, A.

(2002). Cell proliferation in the normal mouse mammary gland and inhibition by phenylbutyrate. Molecular Cancer Therapeutics ,

1(12), 1025-1033.


Guminski, A., Harnett, P., deFazio, A. (2002).

Scientists and clinicians test their metal - back to the future with platinum compounds. Lancet

Oncology , 3(5), 312-318.

2001

Guminski, A., Harnett, P., deFazio, A. (2001).

Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemotherapy and

Pharmacology , 48(3), 229-234.

Guminski, A., deFazio, A., Harnett, P. (2001).

New genetics and cancer chemotherapy. Today's

Life Science (Australia) , 13(2), 36-40.

Arnett-Mansfield, R., Wain, G., Jaworski, R.,

Mote, P., Clarke, C., deFazio, A., Byth, K.

(2001). Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium1. Cancer Research , 61, 4576-4582.

2000 deFazio, A., Chiew, Y., Sini, R., Janes, P.,

Sutherland, R. (2000). Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. International Journal of

Cancer , 87(4), 487-498.

Davis, T., Kennedy, C., Chiew, Y., Clarke, C., deFazio, A. (2000). Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clinical Cancer Research , 6(11),

4334-4342.

Publications for Anna deFazio 2016

Add this document to collection(s)

Add this document to saved

Suggest us how to improve StudyLib